Patients on Alzheimer’s drug Leqembi see benefits over three years, Eisai study says - CNBC
- Patients on Alzheimer’s drug Leqembi see benefits over three years, Eisai study says CNBC
- Lilly and Eisai Diverge on Alzheimer’s Drugs Long-Term Usage Bloomberg
- Eisai, Biogen make case for long-term use of Alzheimer’s drug Leqembi with new data STAT
- Expanding the Knowledge Profile and Treatment Capabilities of Lecanemab: Lynn Kramer, MD, FAAN Neurology Live
- Japan's Eisai eyes blood test for Alzheimer's drug eligibility Nikkei Asia